Dr. CHEN Kan is a scientist-turned-investor who currently serves as a Partner and Co-Head of the Healthcare Sector at Qiming Venture Partners. With extensive experience in biotechnology and pharmaceuticals, Dr. CHEN’s expertise aligns closely with Qiming’s strategic focus on key areas in biotechnology, particularly in cardiovascular, immunology, and oncology therapeutics. Dr. CHEN earned his Ph.D. in Cell Biology from Case Western Reserve University and completed postdoctoral research in immunology at Harvard Medical School. He also holds a Bachelor’s degree in Biological Sciences from Fudan University.

Since joining Qiming Venture Partners in 2016, Dr. CHEN has dedicated himself to biotech investment, successfully identifying over 30 projects, many of which have grown into renowned enterprises. Dr. CHEN serves as a board member of several publicly listed companies on NASDAQ, the Hong Kong Stock Exchange, the Shanghai Stock Exchange, and the Shenzhen Stock Exchange. Currently, he is on the boards of over 20 Qiming portfolio companies, including Insilico Medicine, Lessin Pharmaceuticals, and Elyone Biotech. Dr. CHEN’s leadership and influence in the biotechnology and pharmaceutical sectors have significantly advanced the global strategic transactions of Qiming’s portfolio companies.